Fluciclovine PET/CT improves radiotherapy targeting for recurrent prostate cancer

(Society of Nuclear Medicine) The featured clinical investigation article of the March 2017 issue of The Journal of Nuclear Medicine demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy.